VX-770 Expanded Access Program

Summary

The purpose of this expanded access program is to provide VX-770 prior to its commercial availability to people with cystic fibrosis (CF) who have at least one copy of the G551D-CFTR mutation and who are in critical medical need and who are not eligible for participation in other Vertex-sponsored studies.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications